Project Details
Description
The aim is to study the changes in Galectin-3 & RANKL during disease transition from asymptomatic smouldering myeloma to clinically aggressive symptomatic myeloma to identify ‘markers’ that predict disease progression
| Status | Active |
|---|---|
| Effective start/end date | 2/10/23 → 2/10/24 |
Collaborative partners
- University of Northampton (lead)
- University of Liverpool
- Science and Technology, University of Northampton
- Department of Haematology Peterborough City Hospital
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.